Adverse events in the prophylaxis of haemophilia

Haemophilia

Volumn 9, Issue SUPPL. 1, 2003, Pages 50-56

  Giangrande, Paul L F ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Adverse events; Haemophilia; Inhibitors; Prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9 CONCENTRATE;

ALLERGIC REACTION; ANAPHYLAXIS; ARTICLE; BLEEDING TENDENCY; CATHETER INFECTION; CHILD; CREUTZFELDT JAKOB DISEASE; DISEASE PREDISPOSITION; DISEASE TRANSMISSION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HEMOPHILIA; HEREDITY; HUMAN; IMMUNOPATHOLOGY; INCIDENCE; INDWELLING CATHETER; INFECTION RISK; PRIORITY JOURNAL; RISK ASSESSMENT; SPORT; THROMBOSIS;

EID: 0038779223     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.9.s1.5.x     Document Type: Article

References (30)

1. Royal S, Schramm W, Berntorp E et al. Quality of life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia 2002; 8: 44-50.
2. Schramm W. Blood Safety in the European Community: an Initiative for Optimal Use. European Commission, 1999; 43-5.
3. Hunter N, Foster J, Chong A et al. Transmission of prion diseases by blood transfusion. J General Virol 2002; 83: 2897-2905.
4. Eis-Hubinger AM, Sasowski U, Brackmann H-H. Parvovirus B19 is frequently present in recombinant coagulation factor VIII products. Thromb Haemost 1996; 76: 1120.
5. Azzi A, De Santis R, Morfini M et al. TT virus contaminates first-generation recombinant factor VIII concentrates. Blood 2001; 98: 2571-3.
6. Minor PD. Are recombinant products really infection risk free? Haemophilia 2001; 7: 114-6.
7. Burstyn DG. Contamination of genetically engineered Chinese hamster ovary cells. Dev Biol Stand 1996; 88: 199-203.
8. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
9. Oldenburg El-Maari O, Schwaab R. Inhibitor development in correlation to factor VIII genotypes. Haemophilia 2002; 8 (Suppl. 2): 23-9.
10. Astermark J, Berntorp E, White GC, Kroner BL and the MIBS Study Group. The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development. Haemophilia 2001; 7: 267-72.
11. Mauser-Bunschoten EP, van der Bom JG, Bongers M et al. Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A. Haemophilia 2001; 7: 364-8.
12. Kreuz W, Escuriola Ettingshausen C, Zyschka A et al. Inhibitor development in previously untreated patients with haemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Semin Thromb Haemost 2002; 28: 285-90.
13. Lorenzo JI, Lopez A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: the importance of age. Br J Haematol 2001; 113: 600-3.
14. Van der Bom Mauser-Bunschoten EP, Fischer K, Heijnen CJ, van den Berg HM. Immune response in early infancy. Haemophilia 2002; 8: 546 (abstract 12 PO 69).
15. Dimichele D, Larson A, Tarantino MD. Inhibitor development in haemophiliacs treated shortly after birth: a survey of haemophilia treatment centre physicians. Haemophilia 2002; 8: 545 (abstract 12 PO 65).
16. Poon M-C, Lillicrap D, Hensman C, Card R, Scully M-F. Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study. Thromb Haemost 2002; 87: 431-5.
17. Giangrande PLF for the Kogenate Bayer Study Group. Safety and efficacy of Kogenate Bayer in previously untreated patients (PUP's) and minimally treated patients (MTP's). Haemophilia 2002; 8 (Suppl. 2): 19-23.
18. Hoots K, Canty D. Clotting factor concentrates and immune function in haemophilic patients. Haemophilia 1998; 4: 704-13.
19. Ljung R, Aronis-Vournas S, Kurnik-Auberger K et al. Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries. Haemophilia 2000; 6: 619-24.
20. Liesner RJ, Vora AJ, Hann IM, Lilleyman JS. Use of central venous catheters in children with severe congenital coagulopathy. Br J Haematol 1995; 97: 203-7.
21. Collins Khair KS, Liesner R, Hann IM. Complications experienced with central venous catheters in children with congenital bleeding disorders. Br J Haematol 1997; 99: 206-8.
22. Evatt BL, Farrugia A, Shapiro ADF, Wilde JT. Haemophilia 2002: emerging risks of treatment. Haemophilia 2002; 8: 221-9.
23. Santagostino E, Gringeri A, Muca-Perja M, Mannucci PM. A prospective clinical trial of implantable central venous access in children with haemophilia. Br J Haematol 1998; 102: 1224-8.
24. Yee TT, Beeton K, Griffioen A, Harrington C, Miners A, Lee CA. Experience of prophylaxis treatment in children with severe haemophilia. Haemophilia 2002; 8: 76-82.
25. Morado M, Jiminez-Yuste V, Villar A et al. Complications of central venous catheters in patients with haemophilia and inhibitors. Haemophilia 2001; 7: 551-6.
26. Medeiros D, Miller KL, Rollins Buchanan GR. Contrast venography in young haemophiliacs with implantable central venous access devices. Haemophilia 1998; 4: 10-5.
27. Journeycake JM, Quinn CT, Miller KL, Zajac JL, Buchanan GR. Catheter-related deep venous thrombosis in children with hemophilia. Blood 2001; 98: 1727-31.
28. Vidler V, Richards M, Vora A. Central venous catheter-associated thrombosis in severe haemophilia. Br J Haematol 1999; 104: 461-4.
29. Blanchette VS, Al-Tabolsi H, Stain MM. High risk of central venous line-associated thrombosis in boys with haemophilia. Blood 1999; 94: 818a (Abstract).
30. Escuriola-Ettinghausen C, Kurnik K, Schobess R, Kreuz Halimeh S, Pollman H, Nowak-Göttl U. Catheter-related thrombosis in children with haemophilia A: evidence of a multifactorial disease. Blood 2002; 99: 1499-500.